BCM
SNDX icon

Bluefin Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bluefin Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-21,510
Closed -$161K – 726
2019
Q3 		$161K Buy
+21,510
New +$196K 0.02% 287

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bluefin Capital Management's SNDX Position: Q4 2019 in Review

Bluefin Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2019, closing a stake of 21,510 shares — an estimated $161K sold.

Bluefin Capital Management first reported a position in SNDX in Q3 2019 and held it in 1 quarter. The position peaked at $161K in Q3 2019. 72 funds tracked by Wall St. Rank hold SNDX as of Q4 2019.

  • Bluefin Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Bluefin Capital Management sold 21,510 Syndax Pharmaceuticals shares in Q4 2019, an estimated $161K.
  • Bluefin Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Bluefin Capital Management's Syndax Pharmaceuticals position peaked at $161K in Q3 2019.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2019.

Based on Bluefin Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.